Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ICML 2019 | Zanubrutinib in mantle cell lymphoma: updated safety and efficacy data

Constantine Tam • 20 Jun 2019
ICML 2019
B-Cell Lymphoma Lymphoma Mantle Cell Lymphoma Non-Hodgkin Lymphoma Zanubrutinib

“Constantine Tam, MD, FRACP, FRCPA, Peter MacCallum Cancer Centre, Melbourne, Australia, presents the updates safety and efficacy data from the Phase I trial of zanubrutinib in mantle cell lymphoma (MCL). This interview took place at the 15th International Conference on Malignant Lymphoma (ICML), in Lugano, Switzerland.

More from Constantine Tam

1:13
ALPINE trial update: zanubrutinib continues to show superior efficacy to ibrutinib in CLL
Constantine Tam • 11 Dec 2023
2:06
The potential of BGB-16673, a BTK degrader, for the treatment of R/R B-cell malignancies
Constantine Tam • 11 Dec 2023
1:52
SYMPATICO: Primary analysis results of ibrutinib plus venetoclax for patients with R/R MCL
Constantine Tam • 11 Dec 2023
2:36
Sonrotoclax plus zanubrutinib combination shows promise in treatment-naïve CLL/SLL
Constantine Tam • 11 Dec 2023

Related Videos

3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
2:11
The role of CAR-T therapy for lymphoma in 2024: expert session highlights
Sridhar Chaganti • 16 Apr 2024
1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals